Canadian Adverse Drug Reaction Newsletter
Volume 7 · Number 4 · October 1997
In This Issue
Calcium-channel blockers
Azithromycin
Newsletter survey results
Communiqué
Update on calcium-channel blockers
The Therapeutic Products Directorate recently undertook a comprehensive
review of the safety of calcium-channel blockers (CCBs), with advice obtained
from an independent Ad Hoc Expert Advisory Committee (EAC) convened especially
to assist in this review.
As a result of this review, a "Dear Doctor Letter" was issued on June 25, 1997,
which reemphasized the approved uses of CCBs in Canada. It affirmed that immediate-release
nifedipine capsules are not indicated in the management of essential hypertension
and that CCB preparations, when approved for the treatment of hypertension in
Canada, are limited to second-line therapy after diuretics and/or -blockers,
for which beneficial clinical outcome data exist. CCBs are not indicated for
the treatment of congestive heart failure or unstable angina, or immediately
following myocardial infarction.
Use of immediate-release nifedipine capsules is not recommended for the acute
reduction of blood pressure. When used in this way, the time course and magnitude
of blood pressure response is unpredictable. Serious adverse events, including
myocardial infarction, stroke and death, have occurred in this setting.1
Furthermore, attention should be drawn to the route of biotransformation of
CCB preparations, namely by the cytochrome-P-450 system. This is particularly
relevant for dihydropyridine CCBs, such as nifedipine, nicardipine and felodipine,
which are metabolized primarily by the CYP 3A4 isoenzyme and which may therefore
interact significantly with other compounds that are metabolized by this same
enzyme or that affect its activity. In general, the potential clinical significance
of drug interaction with these dihydropyridines varies inversely with their
absolute bioavailability. For details, please consult relevant product monographs.
Grapefruit juice, in quantities equivalent to a normal breakfast glassful, effectively
inhibits the isoenzyme CYP 3A4 up to at least 24 hours after ingestion. Therefore,
it is prudent to avoid the ingestion of grapefruit juice or grapefruit when
a dihydropyridine is being taken.2
The Ad Hoc EAC also recommended that thorough monitoring and data evaluation
be conducted for bleeding episodes in all ongoing and future clinical trials
in patients treated with CCBs, because preliminary evidence exists that indicates
a possible association. In order to allow us to evaluate this potential adverse
drug reaction more fully, we welcome and encourage you to provide us with reports
of any suspected drug reactions with CCBs, including those associated with bleeding.
Références
1.Grossman E, Messerli F, Grodzicki T, Kowey P. Should a moratorium
be placed on sublingual nifedipine capsules given for hypertensive emergencies
and pseudoemergencies? JAMA 1996;276:1328-31.
2.Bailey DG, Arnold MO, Spence JD. Grapefruit juice and drugs.
How significant is the interaction? Clin Pharmacokinet 1994;26(2):91-8.
This article is under the direction of: Guy Beaulieu, PhD,
Mick Gelsema, PhD, and Ken Gruchalla, MD
Severe iatrogenic hepatitis associated with azithromycin
The Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
reviewed 2 reports of severe iatrogenic hepatitis in patients on azithromycin.
Both patients received 500 mg as a single dose on the first day followed by
250 mg once daily for 4 subsequent days.
The first patient, a 45-year-old man, was diagnosed with severe iatrogenic toxic
hepatitis. The patient had been given azithromycin for an episode of acute bronchitis;
he had not been taking any concomitant drugs. No other medical problems were
reported. Within 7 weeks after beginning the course of azithromycin, malaise,
anorexia, fatigue, myalgia and nausea had developed, followed by fever and jaundice.
On admission to hospital, he was icteric. The results of antinuclear antibody
test and the serology tests for hepatitis A, B and C were negative. His liver
enzyme levels were elevated as follows: ALT 1091 U/L (normal range 0-35), AST
1750 U/L (normal range 0-35) and alkaline phosphatase 232 U/L (normal range
30-120). His bilirubin level was 565 mol/L (normal range 2-18). Liver biopsy
was consistent with a massive necrosis (mostly centrolobular), infiltrated and
enlarged portal tracts with numerous eosinophils and mononuclear elements. He
subsequently underwent a liver transplantation 78 days after completing his
treatment with azithromycin and was recovering at the time of reporting.
The second patient, an 85-year-old man with a history of 3 myocardial infarctions
in the last 5 years, atrial fibrillation, ulcers, urinary problems and asthma,
was treated for bronchitis with azithromycin. Within 6 weeks after beginning
azithromycin he became ill and was hospitalized because of acute hepatitis.
He was on 12 concomitant drugs including acetylsalicylic acid, enalapril, furosemide,
glyburide, lovastatin, omeprazole and terazosin. Some of these drugs have the
potential to cause liver injury. Liver biopsy showed hepatocellular damage compatible
with a drug reaction, and his bilirubin level was greater than 300 mol/L.
When he started his treatment with azithromycin, 52 days before his death, there
was no indication of liver dysfunction.
Results from controlled clinical trials reveal that the overall incidence of
adverse events associated with azithromycin is about 12%.1
The current product monograph indicates that increased liver enzyme values are
potential side effects in patients receiving azithromycin. Rare but potentially
serious side effects, including cholestatic jaundice, have occurred. The monograph
also states that drug-induced hepatitis and hepatic necrosis "have been reported
in patients under conditions (e.g., open trials, marketing experience) where
a causal relationship is uncertain or in patients treated with significantly
higher than the recommended doses for prolonged periods."
The first case reminds health professionals that azithromycin therapy has the
potential to be associated with centrolobular necrosis in patients with no history
of liver disease. These 2 cases also emphasize the need for awareness of serious
hepatotoxic effects and to ensure that the prescribing of azithromycin should
be undertaken with caution in patients with significant hepatic disease.
Référence
1.Charles L, Segreti J. Choosing the right macrolide antibiotic.
Drugs 1997;53(3):349-57.
This article is under the direction of: Pascale Springuel,
BPharm
Satisfaction with the Canadian ADR Newsletter
-- survey results
A questionnaire (English and French) was included in the October
1996 issue of the Canadian Adverse Drug Reaction Newsletter, with a view to
evaluating the newsletter's usefulness and obtaining suggestions for improvement.
The distribution occurred over a period of approximately 5 to 6 months because
of the mailing schedules of the various pharmacist licensing authorities.
The survey contained questions on the content of the newsletter, relevance to
practice, satisfaction with the type of information, satisfaction with the mailing
schedule and means of distribution, as well as demographic data. Questions were
either of the Yes/No type or based on a 4-point Likert scale anchored with levels
of interest between None and High. There also were opportunities to make comments.
Analysis
Data capture was done using the software Epi Info (Centers
for Disease Control and Prevention, Atlanta), and statistical analyses were
done using SAS software (SAS Institute, Cary, NC). For ease of interpretation
the 4-point Likert scale was divided into 2 categories (High and Moderate v.
Low, None and Other).
Results
A total of 410 completed questionnaires were returned by April
1997. There were responses from 325 pharmacists, 66 physicians, 1 dentist, 5
nurses and 13 nonspecified respondents. One hundred and eight respondents practised
in an institution, and 221 practised in the community.
Over 90% of the respondents considered the newsletter relevant to their practice,
its distribution satisfactory and its length adequate (99.8%, 93.9% and 90.0%
respectively). About 70% did not want a change in the quarterly distribution.
Of the 108 who did suggest a change, 96% were pharmacists. About 46% suggested
a monthly newsletter, and about 42% every second month.
When asked about interest in content, more than 90% indicated the following
ADR topics: for new drugs (less than 5 years on the market), for older drugs,
for individual drugs, and for a class of drugs. For these topics, the proportion
of respondents did not differ much between the 3 main groups (pharmacists, physicians
and others) except for ADRs for a class of drugs, which was chosen by 5% more
pharmacists than physicians. The highest rate of interest was for ADRs for new
drugs (98.1%).
Some topics received mid-level interest scores (overall 70% to 89%). These were:
articles on specific reactions, ADR profiles, list of Drugs of Current Interest,
changes in labelling of ADRs in product monographs, specific topics (e.g., switch
to over-the-counter status), and an annual index. When compared with the previous
topics (of interest to 90% or more of the respondents) the difference in proportions
between the groups was larger, with more pharmacists than physicians indicating
interest. The largest difference (75.1% v. 54.6%) was found for an annual index.
The least popular topics (chosen by less than 70% overall) were for: information
on international safety issues, insertion of an ADR reporting form in the newsletter
and editorials on the CADRMP.
Discussion
Results must be interpreted with caution because of the small
number of respondents. The survey was included in an issue of the newsletter,
and there was no individual follow-up, but only a brief reminder in the Jan.
1, 1997, issue.
The response rate may have been affected by the means of distribution. Because
the newsletter is sent as an insert in a professional journal, or is included
in information mailed out by the provincial licensing body or professional associations
of pharmacists, the motivation to respond to the questionnaire may be less than
if the questionnaire had been mailed separately. Nevertheless, the results provide
valuable information. Most of the respondents were pharmacists. Accordingly,
interpretation of this data is swayed by this particular group. It may also
mean that pharmacists have more interest in receiving information on ADRs than
other health care professionals.
Approximately one-quarter of the respondents provided written comments. Several
compliments on the articles were made; the newsletter was described as a useful
tool that provided important, relevant information on ADRs. There were suggestions
for an index, more timely distribution and direct mailing.
In conclusion, the survey results showed that the main interest is in ADRs for
new drugs. Quarterly distribution is satisfactory, although means of distribution
could be improved.
The results will be used with other information being collected, to plan and
implement further changes.
Prepared by Carole Bouchard, BPharm, Frances Laffey, MSc, and
Wikke Walop, PhD. The contribution by Patricia Leblanc is greatly appreciated.
Communiqué
The purpose of this new section is to increase awareness of
recently reported ADRs. The following cases have been selected on the basis
of their seriousness, or the fact that the reactions do not appear in the product
monograph. They are intended to prompt reporting.
Protease inhibitors
The Therapeutic Products Programme (TPP) is aware of approximately
152 cases worldwide of new or exacerbated diabetes mellitus and hyperglycemia
in HIV-infected patients receiving protease inhibitors. The Canadian reports
received include 6 for Crixivan® (indinavir sulfate) and 2 for InviraseT
(saquinavir mesylate). Three patients recovered from hyperglycemia, 1 started
insulin therapy, but hyperglycemia persisted, 1 died from sepsis, and 3 cases
were of unknown outcome. In 4 of these 8 cases, the patients were known to have
diabetes. However, there is no conclusive evidence to establish a causal relationship
between protease inhibitor therapy and these events. Health Canada will be monitoring
the situation closely as further information becomes available. An information
sheet has been issued by the TPP in this regard.1
Vigabatrin (Sabril®)
A number of reports of ophthalmological abnormalities including
visual field constriction, bilateral optic disc pallor, subtle peripheral
retinal atrophy and optic atrophy associated with the use of vigabatrin
have been collected from various countries by Hoechst Marion Roussel in the
course of international postmarketing surveillance.2
Terconazole (TerazolTM 3 vaginal ovules/cream)
A 25-year-old woman gradually developed erythema multiforme
covering 90% of her body surface a few days after intravaginal administration
of terconazole ovules and suspected topical administration of terconazole vaginal
cream. The situation progressed to Stevens-Johnson syndrome and toxic
epidermal necrolysis within 24 hours. Sepsis developed, and the patient
died from severe complications following acute renal failure and subsequent
cardiac arrest. Concomitant medication use included the contraceptive Ortho®
1/35. The patient had used a Lactobacillus herbal preparation 4 to 5
days before using the terconazole.
Fen-phen (a combination of fenfluramine and phentermine)
The TPP has been informed that 33 cases of cardiac valvulopathy
have been reported to the US Food and Drug Administration following the
use of fen-phen. In Canada, 1 case or possibly 2 cases of adverse cardiac events
were reported to the CADRMP. Although the drugs (Ponderal® and Pondimin®
[fenfluramine], Fastin® and Ionamin® [phentermine] as well as Tenuate®
[diethylpropion]) have been approved for use as individual agents for
short-term use (no longer than 3 months) in the management of obesity, their
concomitant use has not been approved either in Canada or in the US. However,
it is known that physicians may prescribe these products in combination. There
is no definitive causal relationship that has yet been confirmed between valvular
heart disease and the combined use of these products; however, the trend is
considered to be serious enough to warrant early intervention. Accordingly,
the TPP has issued an information sheet3,4 advising
physicians against prescribing any combination of anti-obesity drugs until further
information becomes available.
*New developments have arisen since submitting the Newsletter
for printing. Please refer to Health Canada's Warning letter dated September
15, 1997, Warning not to use products containing fenfluramine (Ponderal,
Pondimin) or dexfenfluramine (Redux), for updated information.
Public Inquiries: (613) 957-2991
Heparin
A cluster of reports of retroperitoneal bleeding associated
with the use of heparin products has been received. Hemorrhage is the main adverse
effect of heparin therapy. This risk may be increased in certain patients, such
as the elderly and those taking medication affecting the clotting cascade. The
package insert should be consulted for instructions regarding proper use of
heparin, including monitoring of coagulation parameters and the adjustment of
dosages as required. Different assay methods exist for measuring and expressing
the potency of heparin products. The 2 major units are USP Units and International
Units. However, they are not equivalent5 and thus
cannot be used interchangeably at equivalent doses.
Paroxetine (Paxil®)
A 13-month-old boy with prenatal exposure to paroxetine exhibited
delayed global development. No other drugs had been taken by the mother;
as well, no other obvious causative factors were identified.
A female infant born at 35 weeks' gestation had intraventricular and subarachnoid
bleeding. The mother had been taking paroxetine from the 16th week of pregnancy
until delivery. The baby recovered from the bleeding, but according to the physician
permanent neurological damage may occur.
A 29-year-old woman, while taking paroxetine, experienced a miscarriage
during the first trimester of pregnancy (at 8 weeks). No other drugs were taken
concomitantly.
Références
1.Reports of diabetes and hyperglycemia in patients receiving
protease inhibitors for the treatment of human immunodeficiency virus (HIV).
Ottawa: Therapeutic Products Programme; 1997 July 4.
2.Important Health Canada safety information [letter].
Laval (QC): Hoechst Marion Roussel Canada; 1997 June 27.
3.Heart-valve disease linked to common
diet drug. Can Med Assoc J 1997;157:362.
4.Cardiac adverse reactions in patients following the
use of fen-phen (a combination of fenfluramine and phentermine). Ottawa:
Therapeutic Products Programme, 1997 July 11.
5.Reynolds JEF, editor. Martindale. The extra pharmacopeia
(electronic version). Englewood (CO): Micromedex, Inc; 1995.
This section is under the direction of: Amal Hélal,
BSc Phm, in collaboration with Cathy Parker, BSc, Pascale Springuel, BPharm,
and Ann Sztuke-Fournier, BPharm
If you have observed similar cases, please report to
the ADR Reporting Unit, Continuing Assessment Division, Bureau of Drug Surveillance,
AL 4103B1 Ottawa ON K1A 1B9; fax 613 957-0335; or to a participating regional
centre. (Check the CPS Clin-Info section on ADR reporting for complete
addresses and to obtain a copy of the reporting form.)
This newsletter can be found on line, under Publications, at
the following new address:
http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/ar-ei_index_e.html
Canada
The Canadian Adverse Drug Reaction Monitoring Newsletter is prepared and funded
by the Therapeutic Products Directorate, Health Canada and published in the
CMAJ regularly.
|